Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. today announced the appointment of Sef Kurstjens, M.D., Ph.D. as the head of Research and Development activities in the U.S. As Senior Vice...
Read more about Astellas Appoints New U.S. Research & Development Head
Tarceva Now Approved for Advanced Non-Small Cell Lung Cancer and Pancreatic Cancer MELVILLE, N.Y., and SOUTH SAN FRANCISCO, Calif., Nov. 3 /PRNewswire- FirstCall/ -- OSI Pharmaceuticals, Inc....
MELVILLE, N.Y. and SOUTH SAN FRANCISCO, Calif.--Nov. 2, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that the U.S. Food and Drug Administration...
Vancouver, Canada, October 19, 2005 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. today announced the initiation of an open-label...
MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 12, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) today reiterated its confidence in the launch year performance and long-term prospects of its flagship...
MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 21, 2005--OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the...
MELVILLE, NY & SAN FRANCISCO--(BUSINESS WIRE)--Sept. 13, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. (NYSE: DNA) announced today that the Oncologic Drug Advisory Committee...
PALO ALTO, Calif. and DEERFIELD, IL, August 10, 2005 – CV Therapeutics, Inc. (Nasdaq: CVTX) and Astellas Pharma US, Inc. announced today that the first of two pivotal Phase 3 studies of...
Read more about Regadenoson Meets Primary Endpoint in First Phase 3 Trial
MELVILLE, N.Y.--Aug. 8, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the Oncologic Drugs Advisory Committee (ODAC) panel will review at its September 13, 2005 meeting the...
MELVILLE, N.Y.--(BUSINESS WIRE)--July 13, 2005--OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) announced today that Health Canada has approved Tarceva® (erlotinib) for the treatment of patients with...
Follow U.S. news
